The New Outlook of Monoclonal Antibodies in Neutralizing Target Cells in COVID-19

Background: The deadly arrival of novel coronavirus (COVID-19) in late December 2019, caused by the Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) has emerged worldwide causing a pandemic. The World Health Organization (WHO) has proved ineffectiveness against existing medications this influenced the prompt identification of Monoclonal antibodies (mAbs) which plays a vital role as the prophylactic application that helps in developing new interventions. Objectives: To study the effect of mAbs in high-risk individuals in treating COVID-19. Methodology: The recent studies related to the aim of the review were undertaken through a literature search to analyze the importance of mAbs in combating SARS-CoV-2. Results: In several countries even though vaccines have reached the Emergency Use Authorization (EUA) people still rely on traditional medications. Besides repurposed drugs, recently many mAbs targeting S-protein of SARS-CoV-2 have been signed up for clinical trials. Currently, no specific neutralizing mAbs have been reported for SARS-CoV-2 and it may take several years for such antibodies to be readily available. The development of mAbs for preventing the SARS-CoV 2 infection is challenged by the threat of antibody-dependent enhancement, antibody-resistant against SARS-CoV-2 variants, acute respiratory infections, clinical trials and risk assessment, and inexplicable. The clinical trial data proved that there is no life-threatening Adverse Drug Reactions (ADR) occurred during mAbs therapy for COVID-19 patients. Conclusion: Establishing monoclonal antibodies will continue to be the best prophylactic application as it minimizes the risk of hospitalization in the high-risk individuals affected by SARS-CoV-2 infection. Keywords: COVID-19, Monoclonal antibodies (mAbs), Emergency Use Authorization (EUA), Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2)